108 | Chapter 4 33. Dengler, H. S., G. V Baracho, S. A. Omori, S. Bruckner, K. C. Arden, D. H. Castrillon, R. A. DePinho, and R. C. Rickert. 2008. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat. Immunol. 9: 1388–1398. 34. Ochiai, K., M. Maienschein-Cline, M. Mandal, J. R. Triggs, E. Bertolino, R. Sciammas, A. R. Dinner, M. R. Clark, and H. Singh. 2012. A self-reinforcing regulatory network triggered by limiting IL-7 activates pre-BCR signaling and differentiation. Nat. Immunol. 13: 300–307. 35. Calnan, D. R., and A. Brunet. 2008. The FoxO code. Oncogene 27: 2276–2288. 36. Huang, H., K. M. Regan, F. Wang, D. Wang, D. I. Smith, J. M. A. van Deursen, and D. J. Tindall. 2005. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl. Acad. Sci. U. S. A. 102: 1649–1654. 37. Fraser, M., S. M. Harding, H. Zhao, C. Coackley, D. Durocher, and R. G. Bristow. 2011. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 10: 2218–2232. 38. Sekulić, A., C. C. Hudson, J. L. Homme, P. Yin, D. M. Otterness, L. M. Karnitz, and R. T. Abraham. 2000. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60: 3504– 3513. 39. Rhodes, N., D. A. Heerding, D. R. Duckett, D. J. Eberwein, V. B. Knick, T. J. Lansing, R. T. McConnell, T. M. Gilmer, S.-Y. Zhang, K. Robell, J. A. Kahana, R. S. Geske, E. V Kleymenova, A. E. Choudhry, Z. Lai, J. D. Leber, E. A. Minthorn, S. L. Strum, E. R. Wood, P. S. Huang, R. A. Copeland, and R. Kumar. 2008. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68: 2366–2374. 40. Levy, D. S., J. A. Kahana, and R. Kumar. 2009. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 113: 1723– 1729. 41. Altomare, D. A., L. Zhang, J. Deng, A. Di Cristofano, A. J. Klein-Szanto, R. Kumar, and J. R. Testa. 2010. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin. Cancer Res. 16: 486–496. 42. Söderberg, O., M. Gullberg, M. Jarvius, K. Ridderstråle, K.-J. Leuchowius, J. Jarvius, K. Wester, P. Hydbring, F. Bahram, L.-G. Larsson, and U. Landegren. 2006. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3: 995–1000. 43. Matsuoka, S., B. A. Ballif, A. Smogorzewska, E. R. McDonald III, K. E. Hurov, J. Luo, C. E. Bakalarski, Z. Zhao, N. Solimini, Y. Lerenthal, Y. Shiloh, S. P. Gygi, and S. J. Elledge. 2007. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (80-. ). 316: 1160–1166. 44. Gatei, M., D. Young, K. M. Cerosaletti, A. Desai-Mehta, K. Spring, S. Kozlov, M. F. Lavin, R. A. Gatti, P. Concannon, and K. Khanna. 2000. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat. Genet. 25: 115–119. 45. Lim, D. S., S. T. Kim, B. Xu, R. S. Maser, J. Lin, J. H. Petrini, and M. B. Kastan. 2000. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404: 613–617. 46. Steinel, N. C., B.-S. Lee, A. T. Tubbs, J. J. Bednarski, E. Schulte, K. S. Yang-Iott, D. G. Schatz, B. P. Sleckman, and C. H. Bassing. 2013. The ataxia telangiectasia mutated kinase controls Igκ allelic exclusion by inhibiting secondary Vκ-to-Jκ rearrangements. J. Exp. Med. 210: 233–239. 47. Waanders, E., B. Scheijen, L. T. van der Meer, S. V van Reijmersdal, L. van Emst, Y. Kroeze, E. Sonneveld, P. M. Hoogerbrugge, A. G. van Kessel, F. N. van Leeuwen, and R. P. Kuiper. 2012. The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet. 8: e1002533.
RkJQdWJsaXNoZXIy MTk4NDMw